Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612337 | 0.89 | MET (0.74) | METCYP3A4 | |
| SCHEMBL612830 | 0.88 | MET (0.69) | METCYP3A4 | |
| SCHEMBL611711 | 0.88 | MET (0.74) | METCYP3A4 | |
| SCHEMBL612425 | 0.87 | MET (0.66) | METCYP3A4 | |
| SCHEMBL612426 | 0.85 | MET (0.61) | METCYP3A4 | |
| SCHEMBL3722790 | 0.84 | MET (0.68) | METCYP3A4 | |
| SCHEMBL3724249 | 0.83 | MET (0.64) | METCYP3A4 | |
| SCHEMBL611705 | 0.83 | MET (1.00) | METCYP3A4 | |
| SCHEMBL3719030 | 0.82 | MET (0.70) | METCYP3A4 | |
| SCHEMBL3724257 | 0.82 | MET (0.70) | METCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040987-A1 | DERIVATIVES OF 6-(6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2393792-A1 | DERIVATIVES OF 6-(6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI (FR) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089508-A1 | DERIVATIVES OF 6-(6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040987-A1 | DERIVATIVES OF 6-(6-NH-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | MET, NR1I2, NCOR2 | MET 1/4885CYP3A4 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.